PHOENIX (NCT05021536) is a Phase 3, randomized, placebo-controlled trial in approximately 65 sites across the U.S. and Europe evaluating the safety and efficacy of sodium phenylbutyrate and taurursodiol (also known as ursodoxicoltaurine) in people living with amyotrophic lateral sclerosis (ALS).
If you’d like to receive updates about what’s happening at Amylyx, click subscribe.